Payment overview · 2025
General Payments
$344.23
18 reported records · 13 companies
Healthcare provider profile · identity verified
Robin Rodgers, MD
Allopathic & Osteopathic Physicians|Family Medicine · CARTERSVILLE, GA · NPI 1811958309
Verified facts
What the public records show
CMS Open Payments records show Robin Rodgers, MD received $344.23 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.75 | 16.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.58 | 12.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.65 | 9.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.98 | 9.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $26.36 | 7.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.83 | 7.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.88 | 6.9% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.96 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.34 | 5.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.70 | 5.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.67 | 5.1% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $14.45 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.08 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.23 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.75 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.58 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 84 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 521 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 119 |
| Alprazolam | Alprazolam | 493 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 132 |
| Zolpidem Tartrate | Zolpidem Tartrate | 331 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 61 |
| Glipizide | Glipizide | 235 | 51 |
| Famotidine | Famotidine | 221 | 72 |
| Metformin Hcl | Metformin Hcl | 215 | 55 |
| Alendronate Sodium | Alendronate Sodium | 202 | 50 |
| Lisinopril | Lisinopril | 198 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 184 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 46 |
| Tramadol Hcl | Tramadol Hcl | 169 | 30 |
| Gabapentin | Gabapentin | 165 | 28 |
| Ezetimibe | Ezetimibe | 156 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 38 |
| Omeprazole | Omeprazole | 124 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 29 |
| Jardiance | Empagliflozin | 105 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 103 | 26 |
| Celecoxib | Celecoxib | 101 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 34 |
| Sertraline Hcl | Sertraline Hcl | 94 | 25 |
| Azithromycin | Azithromycin | 92 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 24 |
| Farxiga | Dapagliflozin Propanediol | 84 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 21 |
| Losartan Potassium | Losartan Potassium | 75 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 71 | 22 |
| Furosemide | Furosemide | 68 | 28 |
| Memantine Hcl | Memantine Hcl | 68 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 16 |
| Meclizine Hcl | Meclizine Hcl | 63 | 23 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 17 |
| Trazodone Hcl | Trazodone Hcl | 59 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 15 |
| Ozempic | Semaglutide | 58 | 11 |
| Carvedilol | Carvedilol | 57 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 20 |
| Nitroglycerin | Nitroglycerin | 57 | 46 |
| Cefuroxime | Cefuroxime Axetil | 56 | 41 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Clonidine Hcl | Clonidine Hcl | 49 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Allopurinol | Allopurinol | 48 | 14 |
| Valsartan | Valsartan | 48 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Niacin Er | Niacin | 41 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 15 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 32 | 15 |
| Kerendia | Finerenone | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Naproxen | Naproxen | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.23 · 18 records | ABBVIE INC. | ACCRUFER, CAPLYTA, ELIQUIS, FARXIGA, FFRct, Flector, GEMTESA, JARDIANCE, Licart, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, Tirosint, UBRELVY, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error